Biscayne

Biscayne Neurotherapeutics was a clinical-stage biotechnology company focused on developing novel therapies for serious central nervous system disorders, with a primary emphasis on refractory epilepsy. The company's lead program, BIS-001, was a synthetic, extended-release formulation of Huperzine A, a potent acetylcholinesterase inhibitor designed to treat patients with difficult-to-control seizures, including those with Dravet syndrome. By utilizing specialized formulation technology, Biscayne aimed to provide high brain levels of the therapeutic agent while minimizing systemic side effects. In addition to its neurology pipeline, the company's predecessor, Biscayne Pharmaceuticals, explored growth hormone-releasing hormone (GHRH) antagonists for oncology indications. In September 2018, Biscayne Neurotherapeutics was acquired by Supernus Pharmaceuticals to strengthen its portfolio of CNS-focused clinical assets.